
Does Medicare Cover BCG Treatment for Bladder Cancer?
BCG is an immunotherapy treatment. Medicare may cover BCG when medically necessary to treat certain types of bladder cancer or after a transurethral resection of bladder tumor (TURBT).
Bacillus Calmette-Guerin (BCG) is the standard immunotherapy drug for bladder cancer. Immunotherapy uses your own immune system to attack cancer cells. With BCG, the doctor inserts a catheter into your bladder to deposit a drug made from a weakened strain of Mycobacterium bovis, a vaccine for tuberculosis.
Original Medicare (parts A and B) covers approved treatments and services for bladder cancer that your healthcare team deems medically necessary, which can include BCG.
Read on to learn about when Medicare might cover BCG, your eligibility for coverage, and your anticipated costs.
Are you eligible for BCG treatment for bladder cancer with Medicare?
Doctors tend to recommend BCG treatment for carcinoma in situ and non-muscle invasive bladder cancer, which includes noninvasive (stage 0) and minimally invasive (stage 1) bladder cancers.
They also typically would suggest it after you've received a procedure known as transurethral resection of bladder tumor (TURBT) to reduce your chance of the cancer returning.
Generally, Original Medicare should approve BCG if you need it under these circumstances. Part A will cover it while you're hospitalized, whereas Part B will cover it if you get the treatment as an outpatient. If you're enrolled in Medicare Advantage (Part C), you should receive the same coverage.
Is Anktiva covered by Medicare?
The U.S. Food and Drug Administration (FDA) has approved the drug Anktiva for use alongside BCG treatment. Like BCG, Anktiva is administered into the bladder. Medicare Part A and B may cover Anktiva if medically necessary, with covered BCG treatment.
Note that Parts A and B should cover the drug itself and not just the catheter administration procedure. This is because you cannot administer the medication to yourself, in which case it would fall under the coverage of Medicare Part D.
That said, currently there is a shortage of the BCG drug. For this reason, according to the Centers for Medicare & Medicaid Services (CMS), Medicare may approve your treatment at a dose less than the usual dose of 81 milligrams (mg) or 1 vial per session.
How much does BCG treatment for bladder cancer cost?
A 2021 study analyzed the administration of BCG therapy within the Veterans Affairs Health System between 2000 and 2015. After one year, the median cost was around $29,459, increasing to $55,267 by two years, and reaching $117,361 at five years.
That said, your share of this cost after your Medicare coverage kicks in depends on the part of Medicare responsible for your coverage. Under Part B, after you've met the 2025 deductible of $257, Part B will pay for 80% of any covered treatment or service. You also have to pay a monthly premium, which starts at $185, depending on your income.
Under Part A, in most cases, you don't have a premium, though you must meet a $1,676 deductible. Once you do, Part A will cover your treatment fully for the first 60 days of hospitalization. After that, you begin to incur a daily cost that increases over time until you become responsible for the full, remaining cost.
If you're covered by Part C, your plan is managed by a private insurer, which means your premium, deductible, and coinsurance depend on your plan. According to the Centers for Medicaid & Medicare (CMS), the average monthly premium for Part C plans is around $17.00 in 2025.
In addition, to remain enrolled in a Part C plan, you still have to pay the Part B premium. That said, some Part C may cover your Part B premium.
Where can you get help with the cost of BCG treatment for bladder cancer?
Several factors affect the cost of treating bladder cancer, including:
how aggressive the cancer is
the stage at which it was diagnosed
the treatment prescribed by your doctor
Managing your medical expenses starts with ensuring that your doctor accepts your Original Medicare or Part C plan.
If you're enrolled in Original Medicare, you can also consider enrolling in a Medicare supplement plan (Medigap) to help with out-of-pocket costs, such as copayments and deductibles.
You can choose from 10 different plans, depending on factors like your location and coverage needs. However, you cannot use Medigap with Medicare Advantage (Part C) plans.
You may also wish to check if you qualify for a Medicare Savings Program (MSP) and Extra Help, and if you might dually qualify for Medicare and Medicaid. Outside of Medicare, you may wish to check non-profit financial assistance programs.
What other treatments does Medicare cover for bladder cancer?
Medicare Part A covers inpatient hospital stays, including cancer treatments and diagnostics you receive as an inpatient. Part A also offers:
some coverage for care at home, such as skilled nursing and physical therapy
limited coverage for care in a skilled nursing facility after 3 days in the hospital
care in a hospice
In the case of medically necessary outpatient treatments and services to treat bladder cancer, Medicare Part B covers:
visits with your doctor (including oncologists and other specialists)
diagnostic testing (lab tests, ultrasound, etc.)
many chemotherapy drugs administered through an IV at your doctor's office or a clinic
some chemotherapy drugs administered orally
outpatient clinic radiation treatments
durable medical equipment, such as feeder pumps and wheelchairs
Any treatment drugs you can take yourself would fall under Part D coverage. That said, Medicare may not cover every medication. Always confirm coverage and expected costs before receiving treatment. If Medicare doesn't cover the treatment you need, discuss payment plans or other options with your doctor.
Takeaway
Medicare covers treatment and services for bladder cancer; however, you may still have significant out-of-pocket costs depending on factors like recommended treatment or the stage of your cancer.
You can work with your doctor to develop a treatment plan that maximizes your Medicare coverage.
If you have additional coverage, such as a Medicare Part D (prescription drug) plan or a Medigap (Medicare supplement) plan, many of your out-of-pocket costs will be covered.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
29 minutes ago
- Forbes
Musk Follows Harvard In Biting The Hand That Feeds
Elon Musk and Harvard Both Bite the Governmental Hand that Feeds Them From an early age, children are taught essential lessons: do not play with fire, do not pet strange dogs, and if one cannot swim, stay out of the deep end. Another timeless rule—often forgotten by those in positions of immense wealth and influence—is this: do not bite the hand that feeds you. This lesson, while simple, has profound implications in the real world. It applies just as readily to billionaires and institutions as it does to children on a playground. Yet recent actions by both Elon Musk and prominent academic institutions—most notably Harvard, but also Columbia, MIT, and others—suggest that even the most successful individuals and organizations are capable of ignoring foundational wisdom. Harvard set the tone. Amid growing political scrutiny and a shifting cultural landscape, the university has drawn intense criticism over its handling of campus protests, particularly those involving slogans such as 'from the river to the sea.' The administration's decision to defend even the most controversial speech—widely viewed by many as antisemitic—has triggered investigations and jeopardized billions in tax-exempt status and government research funding. This raises a critical question: is this truly the hill worth dying on? Is preserving the right to controversial protest slogans worth risking Harvard's institutional future? It is doubtful that most students and faculty would knowingly trade funding, grants, and prestige for this fight. Elon Musk, the world's richest man, has now followed suit—this time turning his attention toward President Donald Trump, with whom he has launched a high-profile and personal feud. What makes this move especially striking is that President Trump is not a distant figure or a fading influence. He is once again sitting in the White House, wielding executive authority over regulatory agencies, defense contracting, and infrastructure initiatives—all areas that directly affect Musk's companies. Tesla, SpaceX, and xAI have flourished in part because of government partnership. SpaceX alone holds multibillion-dollar contracts with NASA and the Department of Defense. Tesla has benefitted from years of energy subsidies and EV tax incentives. Picking a fight with the sitting president—regardless of personal conviction—puts this entire ecosystem at risk. And again the question must be asked: is this battle worth the damage? Whatever principle Musk may be defending, the consequences extend far beyond himself. Shareholders, employees, and retail investors—many of whom placed their trust and savings in his leadership—are the ones left exposed. The parallel between Harvard and Musk is striking: both have been immensely successful, aided in large part by government funding, favorable regulation, and public goodwill. And both have, for different reasons, chosen to confront the very institutions and leaders that have helped sustain their growth. There is precedent for how this ends. Jack Ma, once the most powerful entrepreneur in China, famously criticized the Chinese government. The backlash was immediate and absolute. His companies were dismantled. His IPO was cancelled. His wealth and influence evaporated almost overnight. Even in less authoritarian systems, the lesson holds: those who antagonize the systems that support them may not survive the consequences. While Musk's personal net worth has dropped from nearly $450 billion to approximately $300 billion, the impact is more symbolic than practical for him. But for millions of investors, employees, and stakeholders, these battles matter. Market volatility, regulatory backlash, and reputational risk all come with tangible financial costs—costs borne not just by Musk himself, but by those who have trusted and invested in his vision. The same applies to Harvard and peer institutions. Their leadership may believe they are standing on principle, but the price of alienating government agencies and key financial backers could reshape the long-term trajectory of these universities. The erosion of public trust, the loss of bipartisan support, and the potential withdrawal of federal funding pose existential threats. Leadership—whether in business or academia—requires more than conviction. It requires judgment, timing, and the discipline to separate personal ideology from institutional responsibility. Founder-led companies often outperform when leaders are focused, visionary, and measured. But when ego replaces strategy, the consequences can be swift and severe. No one is demanding absolute political alignment or silence in the face of controversy. No one is asking Elon Musk to wear a MAGA hat. But his recent actions have been so volatile, so self-destructive, that investors may soon be tempted to hand him something else entirely—a MEGA hat: Make Elon Great Again. In today's polarized environment, the margin for error has narrowed. And for those who owe much of their success to public support—whether in Silicon Valley or the Ivy League—biting the hand that feeds is not just unwise. It is unsustainable. ---------------------------------- Disclosure: Past performance is no guarantee of future results. Please refer to the following link for additional disclosures: Additional Disclosure Note: The author has an affiliation with ERShares and the XOVR ETF. The intent of this article is to provide objective information; however, readers should be aware that the author may have a financial interest in the subject matter discussed. As with all equity investments, investors should carefully evaluate all options with a qualified investment professional before making any investment decision. Private equity investments, such as those held in XOVR, may carry additional risks—including limited liquidity—compared to traditional publicly traded securities. It is important to consider these factors and consult a trained professional when assessing suitability and risk tolerance.


CNET
34 minutes ago
- CNET
Stay Hydrated With Stanley Drinkware, Now Up to 40% Off for Father's Day
If staying hydrated is on your list this summer (as it should be), you need a water bottle that's not just big enough but also keeps your water cold for hours on end. Stanley's drinkware is a solid choice, and with current discounts, you don't have to spend a fortune. The brand is currently running its Father's Day sale, with up to 40% off everything from tumblers to pitchers to flasks (lunch boxes too). As someone who's just started taking hydration seriously -- thanks to her Stanley tumbler -- I highly recommend not missing out on these steep discounts. All the deals are around only for a limited time. We don't know how long the sale or the stock is going to last, so you might want to hurry. Some of our top picks from the sale include the 30-ounce Stanley IceFlow 2.0 flip straw tumbler, which comes with an easy-carry handle. This one keeps your drinks cold for up to 20 hours, or iced for up to three days, making it perfect for those long days when you're out and about. It can be yours for just $26 after a 25% discount right now, and you can choose from multiple colors. If you're after a bigger size, consider the 40-ounce tumbler with the same features, now for $34. For people who can't part with their hot coffee or tea even in the summer, the 12-ounce stay-hot camp mug is now available for just $20. And why stop at drinks when you can also grab the 14-ounce Stanley classic food container at a 14% discount? It can keep your food hot or cold for up to 7 hours. Why this deal matters Stanley products are known for their durability and that classic minimalist design, but they often come with a higher price tag. This sale lets you grab some of the top-rated options at a discount of up to 40%, making it a great time to invest in your drinkware or related items for a lot less.

Associated Press
40 minutes ago
- Associated Press
Video shows dolphin calf birth and first breath at Chicago zoo. Mom's friend helped
CHICAGO (AP) — A bottlenose dolphin at a Chicago zoo gave birth to a calf early Saturday morning with the help of a fellow mom, in a successful birth recorded on video by zoo staff. The dolphin calf was born at Brookfield Zoo Chicago early Saturday morning as a team of veterinarians monitored and cheered on the mom, a 38-year-old bottlenose dolphin named Allie. 'Push, push, push,' one observer can be heard shouting in video released by the zoo Saturday, as Allie swims around the tank, the calf's little tail fins poking out below her own. Then the calf wriggles free and instinctively darts to the surface of the pool for its first breath. Also in the tank was an experienced mother dolphin named Tapeko, 43, who stayed close to Allie through her more than one hour of labor. In the video, she can be seen following the calf as it heads to the surface, and staying with it as it takes that first breath. It is natural for dolphins to look out for each other during a birth, zoo staff said. 'That's very common both in free-ranging settings but also in aquaria,' said Brookfield Zoo Chicago Senior Veterinarian Dr. Jennifer Langan in a video statement. 'It provides the mom extra protection and a little bit of extra help to help get the calf to the surface to help it breath in those couple minutes where she's still having really strong contractions.' In a written statement, zoo officials said early signs indicate that the calf is in good health. They estimate it weighs around 35 pounds (16 kilograms) and stretches nearly four feet in length (115-120 centimeters). That is about the weight and length of an adult golden retriever dog. The zoo's Seven Seas exhibit will be closed as the calf bonds with its mother and acclimates with other dolphins in its group. As part of that bonding, the calf has already learned to slipstream, or draft alongside its mother so that it doesn't have to work as hard to move. Veterinarians will monitor progress in nursing, swimming and other milestones particularly closely over the next 30 days. The calf will eventually take a paternity test to see which of the male dolphins at the zoo is its father. Zoo officials say they will name the calf later this summer.